4-(aminomethyl)-1H-pyrrole-2-carboxylic acid;hydrochloride | 1401555-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(aminomethyl)-1H-pyrrole-2-carboxylic acid;hydrochloride
• CAS: 1401555-61-0
• 化学式: C₆H₈N₂O₂*ClH
• 分子量: 176.603
• InChiKey: QZPWDDBOJCTIKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.59
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  79.1
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(((tert-butoxycarbonyl)amino)methyl)-1H-pyrrole-2-carboxylic acid 在 盐酸 作用下， 以 水 为溶剂， 反应 4.0h， 以82%的产率得到4-(aminomethyl)-1H-pyrrole-2-carboxylic acid;hydrochloride
  参考文献：
  名称：

  Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase

  摘要：

  Two principal neurotransmitters are involved in the regulation of mammalian neuronal activity, namely, gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, and L-glutamic acid, an excitatory neurotransmitter. Low GABA levels in the brain have been implicated in epilepsy and several other neurological diseases. Because of GABA's poor ability to cross the blood-brain barrier (BBB), a successful strategy to raise brain GABA concentrations is the use of a compound that does cross the BBB and inhibits or inactivates GABA aminotransferase (GABA-AT), the enzyme responsible for GABA catabolism. Vigabatrin, a mechanism-based inactivator of GABA-AT, is currently a successful therapeutic for epilepsy, but has harmful side effects, leaving a need for improved GABA-AT inactivators. Here, we report the synthesis and evaluation of a series of heteroaromatic GABA analogues as substrates of GABA-AT, which will be used as the basis for the design of novel enzyme inactivators. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.08.009

文献信息

• MODULATION OF CHROMOSOME FUNCTION BY CHROMATIN REMODELING AGENTS
  申请人：UNIVERSITE DE GENEVE

  公开号：EP1294406A2

  公开（公告）日：2003-03-26
• LINKED, SEQUENCE-SPECIFIC DNA-BINDING MOLECULES
  申请人：UNIVERSITE DE GENEVE

  公开号：EP1307470A2

  公开（公告）日：2003-05-07
• [EN] LINKED, SEQUENCE-SPECIFIC DNA-BINDING MOLECULES<br/>[FR] MOLECULES LIANT L'ADN, LIEES ET SPECIFIQUES AUX SEQUENCES
  申请人：UNIV GENEVE

  公开号：WO2002004476A2

  公开（公告）日：2002-01-17

  The present invention concerns a DNA-binding molecule, capable of sequence-specific binding to the minor groove of double-stranded DNA, characterised in that it comprises at least two sequence specific DNA-binding elements, covalently linked to each other in tandem orientation by an amphipathic, flexible linker molecule, at least one of said DNA binding elements being non-proteinaceous.
• [EN] MODULATION OF CHROMOSOME FUNCTION BY CHROMATIN REMODELING AGENTS<br/>[FR] MODULATION DE LA FONCTION CHROMOSOMIQUE PAR DES AGENTS REMODELANT LA CHROMATINE
  申请人：UNIV GENEVE

  公开号：WO2002000262A2

  公开（公告）日：2002-01-03

  The present invention concerns a process for modulating the function of a DNA element in a eukaryotic cell, comprising the step of contacting a genomic DNA element, so-called 'chromatin responsive element' (CRE), with a compound having a molecular weight of less than approximately 5 KDa, and having the capacity to bind a sequence-specific manner to said CRE, said step of contacting being carried out in conditions permitting chromatin remodeling of the CRE by said compound, wherein said chromatin remodeling of the CRE alters the activity of one or more other DNA elements, so called 'modulated DNA elements' in the genome.
• Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase
  作者：Dustin D. Hawker、Richard B. Silverman

  DOI：10.1016/j.bmc.2012.08.009

  日期：2012.10

  Two principal neurotransmitters are involved in the regulation of mammalian neuronal activity, namely, gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, and L-glutamic acid, an excitatory neurotransmitter. Low GABA levels in the brain have been implicated in epilepsy and several other neurological diseases. Because of GABA's poor ability to cross the blood-brain barrier (BBB), a successful strategy to raise brain GABA concentrations is the use of a compound that does cross the BBB and inhibits or inactivates GABA aminotransferase (GABA-AT), the enzyme responsible for GABA catabolism. Vigabatrin, a mechanism-based inactivator of GABA-AT, is currently a successful therapeutic for epilepsy, but has harmful side effects, leaving a need for improved GABA-AT inactivators. Here, we report the synthesis and evaluation of a series of heteroaromatic GABA analogues as substrates of GABA-AT, which will be used as the basis for the design of novel enzyme inactivators. (C) 2012 Elsevier Ltd. All rights reserved.